EMA publishes risk levels of experts based on industry connections
This article was originally published in SRA
The European Medicines Agency has published the "risk levels" of all the experts that are involved in its drug regulatory activities, based on the interests they have declared in relation to the pharmaceutical industry1. The risk levels are used together with the declarations of interests to determine the extent to which a particular expert can take part in the agency's drug authorisation and surveillance operations.
You may also be interested in...
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.